Arrowhead (ARWR) Q3 Revenue Drops 41%
Arrowhead Pharmaceuticals (NASDAQ:ARWR), a biotechnology firm focused on developing RNA interference (RNAi) therapeutics, released its fiscal third-quarter earnings on August 7, 2025. The most notable news from the release was a substantial miss on both GAAP revenue and earnings for Q3 FY2025 compared to analyst expectations. The company reported $27.8 million in GAAP revenue, well below GAAP estimates of $46.8 million, and a loss per share of $(1.26) (GAAP), underperforming the $(0.95) GAAP loss analysts had forecasted. Operating losses remained high, but cash and investments rose, strengthening Arrowhead’s balance sheet. The quarter reflected both ongoing financial volatility and continued progress in moving the company’s clinical pipeline toward commercialization.
Source: Analyst estimates for the quarter provided by FactSet.
Arrowhead Pharmaceuticals is a biotechnology company developing RNAi-based therapeutics, focusing on diseases with significant unmet needs. Its main technology, the TRiMTM platform, enables precise targeting of RNA molecules within the body, allowing for the silencing of disease-causing genes in specific tissues. This approach holds potential for treating conditions previously considered untreatable by traditional medicines.
Source Fool.com
